Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vincent Joerg

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Urologic Oncology|June 21, 2022
Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarkerFinn Becker, Anne Offermann, Marie C Roesch, et al.
Human Pathology|July 27, 2021
CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasiaAnne Offermann, Vincent Joerg, Marie C Hupe, et al.
Carcinogenesis|May 5, 2022
Targeting cyclin-dependent kinase 7-association between CDK7 and pMED1 expression in prostate cancer tissueFinn-Ole Paulsen, Duan Kang, Finn Becker, et al.
International Journal of Cancer|July 5, 2019
Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancerFinn Becker, Vincent Joerg, Marie C Hupe, et al.
The American Journal of Pathology|February 19, 2022
Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate CancerAnne Offermann, Vincent Joerg, Finn Becker, et al.
Frontiers in Oncology|January 9, 2019
Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial DiagnosisMarie Christine Hupe, Christian Philippi, Doris Roth, et al.
Scientific Reports|November 27, 2023
EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinomaLorenz Kocheise, Martin Schoenlein, Berit Behrends, et al.
Urologic Oncology|June 11, 2019
TRIM24 as an independent prognostic biomarker for prostate cancerAnne Offermann, Doris Roth, Marie Christine Hupe, et al.
Annals of Hepatology|August 15, 2024
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinomaLouisa Stern, Constantin Schmidt, Lorenz Kocheise, et al.
Frontiers in Immunology|February 8, 2024
Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseLorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Urologic Oncology|June 21, 2022
Up-regulation of POM121 is linked to prostate cancer aggressiveness and serves as a prognostic biomarkerFinn Becker, Anne Offermann, Marie C Roesch, et al.
Human Pathology|July 27, 2021
CDK19 as a diagnostic marker for high-grade prostatic intraepithelial neoplasiaAnne Offermann, Vincent Joerg, Marie C Hupe, et al.
Carcinogenesis|May 5, 2022
Targeting cyclin-dependent kinase 7-association between CDK7 and pMED1 expression in prostate cancer tissueFinn-Ole Paulsen, Duan Kang, Finn Becker, et al.
International Journal of Cancer|July 5, 2019
Increased mediator complex subunit CDK19 expression associates with aggressive prostate cancerFinn Becker, Vincent Joerg, Marie C Hupe, et al.
The American Journal of Pathology|February 19, 2022
Inhibition of Cyclin-Dependent Kinase 8/Cyclin-Dependent Kinase 19 Suppresses Its Pro-Oncogenic Effects in Prostate CancerAnne Offermann, Vincent Joerg, Finn Becker, et al.
Frontiers in Oncology|January 9, 2019
Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial DiagnosisMarie Christine Hupe, Christian Philippi, Doris Roth, et al.
Scientific Reports|November 27, 2023
EpCAM-positive circulating tumor cells and serum AFP levels predict outcome after curative resection of hepatocellular carcinomaLorenz Kocheise, Martin Schoenlein, Berit Behrends, et al.
Urologic Oncology|June 11, 2019
TRIM24 as an independent prognostic biomarker for prostate cancerAnne Offermann, Doris Roth, Marie Christine Hupe, et al.
Annals of Hepatology|August 15, 2024
Efficacy and safety of palliative treatment in patients with autoimmune liver disease-associated hepatocellular carcinomaLouisa Stern, Constantin Schmidt, Lorenz Kocheise, et al.
Frontiers in Immunology|February 8, 2024
Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver diseaseLorenz Kocheise, Ignazio Piseddu, Joscha Vonderlin, et al.
Pageof 2